Do you consider the cancer measurements to be small, thus making the “observation only” protocol correct? — B.A. Dear B.A.: ...

Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.

I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer.

Some men in your situation will choose surgery, radiation or medication to lower testosterone. Some experts recommend ...

Prostate cancer kills 35,000 men a year, according to Dr. Roach. But not all cancers are treated the same way.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...

But the researchers also found this: Among those with intermediate-risk prostate cancer, the percentage who received aggressive treatment climbed from 37.6% to 59.8%. For men with high-risk ...

B.A. A: Prostate cancer can be very aggressive and is responsible ... However, your PSA is between 10-20 ng/mL, so you are in the “favorable intermediate risk” group. Dr. Roach regrets that ...

B.A. Answer: Prostate cancer can be very aggressive and is ... However, your PSA is between 10-20 ng/mL, so you are in the “favorable intermediate risk” group. In this group, active ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...

Abreu also leads focal therapy and artificial intelligence efforts for prostate cancer with USC Urology. The clinical trial is designed for patients with intermediate-risk prostate cancer ...